

## Fast Facts

Founded: 2000

IPO: December 2, 2014

Ticker: HSGX

Exchange: NASDAQ

Shares Out: 24.1 million

Employees: ~50

Analyst Coverage:

- BTIG
- Canaccord
- Cowen
- HC Wainwright
- Needham

## Media Assets



Product Images



Videos



Image Library

## About Histogenics


Histogenics is a leader in the development of restorative cell therapies (RCT) that may offer rapid-onset pain relief and restored function in patients with orthopedic conditions.

## Restorative Cell Therapy Platform

Histogenics' Restorative Cell Therapy (RCT) platform uses an array of proprietary biotech processes and combines breakthroughs in bio-engineering, biomaterials and cell processing to enhance the autologous cartilage repair process. The resulting RCT is functional living cartilage at the time of treatment.

Our first RCT product candidate, NeoCart®, potentially rebuilds a patient's own knee cartilage for rapid onset pain relief and restored function and may delay or prevent osteoarthritis. With a large and growing market in knee cartilage damage, there is a critical need for a novel therapy, such as NeoCart, that is designed to treat pain and get patients back to work and daily activities more rapidly than the current alternatives.

The RCT platform has the potential to be used for a broad range of additional indications, including cartilage for other joints, as well as other tissue types.




# Histogenics

Restorative Cell Therapies for Active Living


## NeoCart®

Histogenics' lead product candidate, NeoCart®, rebuilds patients' knee cartilage to treat pain at the source and to potentially delay or prevent the progression to osteoarthritis. In clinical trials to date, NeoCart, a rigorously studied personalized restorative cell therapy for orthopedic use, demonstrated improved pain relief and return to function in about half the time compared to the standard of care, microfracture.



NeoCart is currently being evaluated in one of the largest prospectively designed, randomized Phase 3 clinical trials in North America evaluating the safety and efficacy of a Restorative Cell Therapy (RCT) to treat knee cartilage damage in 249 adults. The Phase 3 clinical trial is being conducted under a SPA agreement with the U.S. Food and Drug Administration (FDA). Study enrollment was completed in Q2 2017 and topline one-year superiority data is anticipated in Q3 2018.

## Path to Commercialization & Launch



## Leadership

**Adam Gridley**  
Chief Executive Officer &  
President

**Jon Lieber**  
Chief Financial Officer

**Don Haut**  
Chief Business Officer

**Stephen Kennedy**  
Chief Operating Officer

## Board of Directors

**Garheng Kong, M.D.,  
Ph.D.**  
HealthQuest Capital

**Josh Baltzell**  
SightLine Partners

**David Gill**  
Chairman of the Audit  
Committee

**John Johnson**  
Independent Board  
Member

**Michael Lewis**  
Oceana Investment  
Partners

**Adam Gridley**  
Histogenics

**Kevin Rakin**  
High Cape Partners

**Sue Washer**  
Applied Genetic  
Technology Corporation

Contact:

[investorrelations@histogenics.com](mailto:investorrelations@histogenics.com)

[www.histogenics.com](http://www.histogenics.com)